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For the identification of susceptibility loci for primary biliary cirrhosis (PBC), a genome-wide association study (GWAS) was performed in
963 Japanese individuals (487 PBC cases and 476 healthy controls) and in a subsequent replication study that included 1,402 other Japa-
nese individuals (787 cases and 615 controls). In addition to the most significant susceptibility region, human leukocyte antigen (HLA),
we identified two significant susceptibility loci, TNFSF15 (rs4979462) and POU2AF1 (rs4938534) (combined odds ratio [OR] ¼ 1.56, p ¼
2.84 3 1014 for rs4979462, and combined OR ¼ 1.39, p ¼ 2.38 3 108 for rs4938534). Among 21 non-HLA susceptibility loci for PBC
identified in GWASs of individuals of European descent, three loci (IL7R, IKZF3, and CD80) showed significant associations (combined
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(combined p ¼ 1.11 3 106 and 1.42 3 107, respectively) in the Japanese population. These observations indicated the existence of
ethnic differences in genetic susceptibility loci to PBC and the importance of TNF signaling and B cell differentiation for the develop-
ment of PBC in individuals of European descent and Japanese individuals.Primary biliary cirrhosis (PBC, MIM 109720) is a chronic
and progressive cholestatic liver disease, presumably
caused by autoimmune reactions against biliary epithelial
cells, leading to liver cirrhosis and hepatic failure.1 The
incidence and prevalence of PBC range from 0.33 to 5.8
and from 2 to 40 per 100,000 inhabitants, respectively,
in different geographical areas.2 This may indicate the
contribution of environmental or genetic factors in the
development of PBC, whereas the clinical profiles of PBC
are thought to be similar between different ethnicities
and/or different geographical areas, including European-
descent and eastern Asian populations. The high concor-
dance rate in monozygotic twins compared to dizygotic
twins3 and familial clustering of individuals with PBC indi-
cate the involvement of strong genetic factors in the devel-
opment of PBC; however, the pathogenesis of PBC is
still poorly understood. Previous genome-wide association
studies (GWASs) and subsequent meta-analyses have iden-
tifiedHLA and 21 non-HLA susceptibility loci (IL12A [MIM
161560], IL12RB2 [MIM 601642], STAT4 [MIM 600558],
IRF5 [MIM 607218], IKZF3 [MIM 606221], MMEL1 [MIM
120520], SPIB [MIM 606802], DENND1B [MIM 613292],
CD80 [MIM 112203], IL7R [MIM 146661], CXCR5 [MIM
601613], TNFRSF1A [MIM 191190], CLEC16A [MIM
611303], NFKB [MIM 164012], RAD51L1 [MIM 602948],
MAP3K7IP1 [MIM 602615], PLCL2 [MIM 614276],
RPS6KA4 [MIM 603606], TNFAIP2 [MIM 603300], 7p14,
and 16q24) to PBC in individuals of European descent,4–7
indicating the important role of several autoimmune
pathways (i.e., IL12A signaling, TNF/TLR-NF-kB signaling,
and B cell differentiation) in the development of PBC.
However, GWASs for PBC have never been reported for
ethnicities other than European descent, limiting our
knowledge of the genetic architecture of PBC. Here, we
conducted a GWAS for PBC in the Japanese population
to identify host genetic factors related to PBC, which
would not only expand our knowledge of pathogenic
pathways in PBC but also lead to the development of
rationale for therapies in the future.
Samples from2,395 individuals (1,295caseswithPBCand
1,100 healthy volunteers working at the National Hospital
Organization (NHO) in Japanasamedical staffwhodeclared
having no apparent diseases, including chronic liver
diseases and autoimmune diseases [healthy controls]) were
collected bymembers of the Japan PBC-GWASConsortium,
which consists of 31 hospitals participating in the NHO
Study Group for Liver Disease in Japan (NHOSLJ) and 24
university hospitals participating in the gp210 Working
Group in Intractable Liver Disease Research Project Team
of the Ministry of Health and Welfare in Japan. Most of
the case and control samples were collected from themain-
land and the neighboring islands of Japan (Honshu,
Kyushu, and Shikoku). Previous studies have shown that722 The American Journal of Human Genetics 91, 721–728, Octoberthere is little genetic heterogeneity in resident populations
in these areas.8 In fact, the genetic inflation factor was
close to 1.00, and only a small portion of the samples were
identified as outliers in the principal component analysis.
The cases were diagnosed with PBC if they met at least
two of the following internationally accepted criteria:9
biochemical evidence of cholestasis based mainly on
alkaline phosphatase elevation, presence of serum anti-
mitochondrial antibodies, histological evidence of non-
suppurative destructive cholangitis, and destruction of
interlobular bile ducts. The demographic details of PBC
cases are summarized in Table S1, available online. Of the
487 PBC cases in the GWAS, 57 were male and 430 were
female, ages ranged from 33 to 90 years, the median age
was 66 years, 320 cases had early-stage PBC (a stage without
any signs indicating portal hypertension or liver cirrhosis),
110 had late-stage PBC without jaundice (a stage with signs
of portal hypertension or liver cirrhosis but without persis-
tent jaundice), and 57 were at the late stage with jaundice
(persistent presence of jaundice [total bilirubin >2 mg/dl]).
Of the 476 healthy controls in the GWAS, 170 were male
and 306 were female, ages ranged from 25 to 87 years, and
themedian age was 40. Of the 808 PBC cases in the replica-
tion set, 120 were male and 688 were female, ages ranged
from 24 to 85 years, the median age was 61 years, 646 had
early-stage PBC, 121 had late-stage PBC without jaundice,
and 39 were at the late stage with jaundice. Of the 624
healthy controls in the replication set, 271 were male and
353 were female, ages ranged from 24 to 74 years, and the
median age was 33 years. Concomitant autoimmune
diseases are also shown in Table S1. As for inflammatory
bowel diseases such as Crohn disease (CD, MIM 266600)
and ulcerative colitis (UC, MIM 266600), only one out of
1,274 PBC cases had UC, but none had CD. DNA was ex-
tracted from whole peripheral blood with the QIAamp
DNA Blood Midi Kit (QIAGEN, Tokyo).
For the GWAS, we genotyped 1,015 samples (515
Japanese PBC cases and 500 Japanese healthy controls)
using the Affymetrix Axiom Genome-Wide ASI 1 Array,
according to the manufacturer’s instructions. After ex-
cluding three PBC samples with a Dish QC of less than
0.82, we recalled the remaining 1,012 samples (512 cases
and 500 controls) using the Genotyping Console v4.1
software. Here, Dish QC represents the recommended
sample quality control (QC) metric for the Axiom
arrays.10 Of the 600,000 SNPs embedded in the array,
samples with an overall call rate of less than 97% were
also excluded. As a result, 508 cases and 484 controls
were subjected to further analysis. All samples used for
GWAS passed a heterozygosity check, and no duplicated
and related samples were identified in identity by descent
testing. Moreover, principal component analysis found
29 outliers to be excluded via the Smirnov-Grubbs test5, 2012
Figure 1. GWAS Results
From 963 samples (487 Japanese PBC cases and 476 Japanese healthy controls), p values were calculated with a chi-square test for allele
frequencies among 420,928 SNPs.and finally showed that all PBC cases (n ¼ 487) and
healthy controls (n ¼ 476) formed a single cluster together
with the HapMap JPT (Japanese in Tokyo from the CEPH
collection), but not with CHB (Han Chinese in Beijing)
samples (Figure S1, Table S2). These results indicate that
the effect of population stratification was negligible. The
average overall call rates of the remaining 487 PBC cases
and 476 healthy controls were 99.38% (97.15–99.80) and
99.27% (97.01–99.81), respectively.11 We then applied
the following thresholds for SNP quality control during
the data cleaning: SNP call rate R95%, minor allele
frequency R5% in both PBC cases and healthy controls,
and Hardy-Weinberg Equilibrium (HWE) p value R0.001
in healthy controls.12 Of the SNPs on autosomal chromo-
somes and in the pseudoautosomal regions on the X chro-
mosome, 420,928 and 317 passed the quality control filters
and were used for the association analysis, respectively
(Table S3). A quantile-quantile plot of the distribution of
test statistics for the comparison of genotype frequencies
in PBC cases and healthy controls showed that the infla-
tion factor lambda was 1.039 for all the tested SNPs,
including those in the HLA region, and was 1.026
when SNPs in the HLA region were excluded (Figures S2AThe Americand S2B). Table S4 shows the 298 SNPs with p < 0.0001
in the GWAS. All cluster plots for the SNPs with a p <
0.0001 from a chi-square test of the allele frequency model
were checked by visual inspection, and SNPs with ambig-
uous genotype calls were excluded. For the GWAS and
replication study, a chi-square test was applied to a two-
by-two contingency table in an allele frequency model.
Figure 1 shows a genome-wide view of the single-point
association data, which are based on allele frequencies.
We found that the HLA-DQB1 locus (MIM 604305)
had the strongest association with susceptibility to PBC
(rs9275175, odds ratio [OR] ¼ 1.94; 95% confidence in-
terval [CI] ¼ 1.62–2.33, p ¼ 8.30 3 1013) (Figure 1 and
Table S4); this finding was consistent with findings from
previous studies.4–7 In addition to the HLA class II region,
loci TNFSF15 and POU2AF1 showed evidence indicative of
association with PBC (rs4979462, OR ¼ 1.63; 95% CI ¼
1.36–1.95, p ¼ 1.21 3 107 for TNFSF15; rs4938534, OR ¼
1.53; 95% CI ¼ 1.28–1.83, p ¼ 3.51 3 106 for POU2AF1).
In a subsequent replication analysis, 27 SNPs with p <
0.0001 in the initial GWAS were also studied, in addition
to SNPs at the TNFSF15 and POU2AF1 loci. Tagging SNPs
were selected from the regions surrounding TNFSF15 andan Journal of Human Genetics 91, 721–728, October 5, 2012 723
Figure 2. LD Structure, p Values, and OR Plots in the Association Analysis
LD maps (A) around TNFSF15 (chr9: nucleotide position: 116561403–116733452; build 36.3) and (B) around POU2AF1 (chr11: nucle-
otide position: 110684600–110802128; build 36.3). The middle panels show estimates of pairwise r2 for (A) 28 SNPs and (B) 33 SNPs in
the high-density mapping with a total of 2,365 samples used. The bottom panels show p values and OR-based chi-square tests for the
allelic model for the left panels of 963 samples in the GWAS (C), the right panels of 1,402 samples in the replication study (:), and the
combined analysis (>).POU2AF1 (28 and 33, respectively) for high-density associ-
ation mapping (Table S5, Figures 2A and 2B). For this
follow-up replication analysis, an independent set of
1,402 samples (787 Japanese PBC cases and 615 Japanese
healthy controls) and the original set of 963 samples
(487 PBC cases and 476 healthy controls) were genotyped
with the DigiTag213 and custom TaqMan SNP genotyping
assays (Applied Biosystems, Foster City, CA, USA) on the
LightCycler 480 Real-Time PCR System (Roche, Man-
nheim, Germany). The strongest associations identified
in the initial GWAS were replicated in the independent
set of 1,402 samples (OR ¼ 1.52, p ¼ 5.79 3 108 for
rs4979462; OR ¼ 1.29, p ¼ 9.32 3 104 for rs4938534,
Table 1). The combined p values were 2.84 3 1014
(OR ¼ 1.56; 95% CI ¼ 1.39–1.76) for rs4979462 and
2.38 3 108 (OR ¼ 1.39; 95% CI ¼ 1.24–1.56) for
rs4938534 (Table 1), both of which reached the genome-
wide significance level of p < 5 3 108. In contrast, the
other 27 weakly associated SNPs identified in the initial
GWAS (p values <0.0001) were not found to have signifi-
cant associations with PBC (Table S5). Moreover, no
strongly associated SNPs were observed when comparing
PBC cases between the early and late stages (Table S5).724 The American Journal of Human Genetics 91, 721–728, OctoberA haplotype analysis of the TNFSF15 and POU2AF1
regions was conducted with the use of the genotype data
from all 2,365 samples (1,274 PBC cases and 1,091 healthy
controls). Linkage disequilibrium (LD) blocks were
analyzed with Gabriel’s algorithm,14 and five blocks were
observed in the TNFSF15 region and seven blocks in the
POU2AF1 region (Figures 2A and 2B). There were no differ-
ences in the LD blocks between PBC cases and healthy
controls. The risk haplotypes in each region showed a
lower level of association than did the individual SNPs
(p ¼ 8.26 3 1014 for TNFSF15 and p ¼ 1.00 3 104 for
POU2AF1) (Tables S6 and S7).
Next, we focused on data from our initial GWAS in 21
loci that are reportedly associated with susceptibility to
PBC in populations of European descent.4–7 We found
that three such loci (IL7R, IKZF3, and STAT4) had p values
of less than 0.001 and eight other such loci (RAD51L1,
CXCR5, PLCL2, IL12RB2, NFKB1, CD80, DENND1B, and
7p14) showed evidence of marginal associations (p <
0.05) in the initial GWAS in 487 Japanese PBC cases and
476 Japanese healthy controls (data not shown). We geno-
typed three SNPs (rs6890503 for IL7R, rs9303277 for
IKZF3, and rs7574865 for STAT4) in an independent set5, 2012
Table 1. TNFSF15 SNP rs4979462 and POU2AF1 SNP rs4938534 Associated with Susceptibility to PBC
dbSNP rsID
Nearest
Gene
Risk
Allele
Allele
(1/2) Stage
PBC Cases Healthy Controls ORa
11 12 22 RAF 11 12 22 RAF 95% CI p Valueb
rs4979462 TNFSF15 T T/C GWAS 154
(31.8)
244
(50.4)
86
(17.8)
0.57 98
(20.7)
230
(48.5)
146
(30.8)
0.45 1.63
(1.36–1.95)
1.21 3 107
Replication 253
(32.3)
390
(49.7)
141
(18.0)
0.57 131
(21.6)
305
(50.3)
170
(28.1)
0.47 1.52
(1.30–1.76)
5.79 3 108
Combined 407
(32.1)
634
(50.0)
227
(17.9)
0.57 229
(21.2)
535
(49.5)
316
(29.3)
0.46 1.56
(1.39–1.76)
2.84 3 1014
rs4938534 POU2AF1 A G/A GWAS 114
(23.6)
229
(47.3)
141
(29.1)
0.53 151
(31.8)
247
(52.0)
77
(16.2)
0.42 1.53
(1.28–1.83)
3.51 3 106
Replication 179
(22.8)
391
(49.8)
215
(27.4)
0.52 179
(29.4)
299
(49.2)
130
(21.4)
0.46 1.29
(1.11–1.50)
9.32 3 104
Combined 293
(23.1)
620
(48.9)
356
(28.1)
0.52 330
(30.5)
546
(50.4)
207
(19.1)
0.44 1.39
(1.24–1.56)
2.38 3 108
Parenthetical numbers indicate the percentage of allele 11, 12, or 22 among total alleles in PBC cases or healthy controls. The following abbreviations are used:
PBC, primary biliary cirrhosis; RAF, risk allele frequency; and GWAS, genome-wide association study.
aOdds ratio (OR) of minor allele from the two-by-two allele frequency table.
bp value of Pearson’s chi-square test for the allelic model.of 1,402 samples (787 Japanese PBC cases and 615 Japanese
healthy controls) and the original set of 963 samples (487
PBC cases and 476 healthy controls) using the DigiTag213
and custom TaqMan SNP genotyping assays. Two SNPs,
rs6890853 and rs9303277 located in loci IL7R and IKZF3,
respectively, showed significant associations and the
STAT4 locus (rs7574865) showed suggestive association
with PBC in 2,365 Japanese samples (1,274 PBC cases and
1,091 healthy controls) (rs6890853, combined p value ¼
3.66 3 108, OR ¼ 1.47 for IL7R; rs9303277, combined
p value ¼ 3.66 3 109, OR ¼ 1.44 for IKZF3; rs7574865,
combined p value ¼ 1.11 3 106, OR ¼ 1.35 for STAT4)
(Tables S5 and S8).
Moreover, we genotyped 16 additional associated SNPs,
all of which were the same SNPs as identified in previous
studies,4–7 and revealed that six out of 16 SNPs (located
on CXCR5, NFKB1, CD80, DENND1B, MAP3K7IP1, and
TNFAIP2) were replicated (p < 0.05) in 2,365 Japanese
samples (Table S8). The SNP rs2293370, located in the
CD80 locus, showed a significant association and the
NFKB1 locus (rs7665090) showed a suggestive association
with PBC in the Japanese population (rs2293370, com-
bined p value ¼ 3.04 3 109, OR ¼ 1.48 for CD80;
rs7665090, combined p value ¼ 1.42 3 107, OR ¼ 1.35
for NFKB1). Although further study for determining the
primary SNP at each locus is necessary, the remaining ten
loci (RAD51L1, PLCL2, IL12RB2, IRF5, SPIB, RPS6KA4,
CLEC16A, TNFRSF1A, IL12A, and MMEL1) did not show
significant association (p < 0.05) with PBC in the Japanese
population (Table S8).
In the current GWAS in the Japanese population, we
identified two significant susceptibility loci for PBC,
TNFSF15 (rs4979462) and POU2AF1 (rs4938534), which
had not been identified in the previous GWAS in popula-
tions of European descent. In addition, of the 21 PBC
susceptibility loci that have been identified in populationsThe Americof European descent, three loci (IL7R, IKZF3, and CD80)
showed significant associations and two loci (STAT4 and
NFKB1) showed suggestive associations with PBC in the
Japanese population. Eight other loci (RAD51L1, CXCR5,
PLCL2, IL12RB2, DENND1B, MAP3K7IP1, TNFAIP2, and
7p14) also showed marginal associations with PBC in the
Japanese population. These results indicate the presence
of additional important disease pathways (via TNFSF15
and POU2AF1)—differentiation to T helper 1 (Th1) cells
(via IL7R and STAT4), B cell differentiation (via IL7R
and IKZF3), T cell activation (via CD80), and NF-kB
signaling—in addition to the previously reported disease
pathways in the development of PBC in Japanese popula-
tions.
TNFSF15 is a newly described member of the TNF super-
family that interacts with death receptor 3 (DR3 [MIM
603366], also known as TNFRSF25) not only to promote
effector T cell expansion (i.e., Th1 and Th17 cells) and
cytokine production (i.e., interferon-g [IFN-g, MIM
147570]) at the site of inflammation, but also to induce
apoptosis in cells that overexpress DR3.15 Interestingly,
genetic polymorphisms in TNFSF15 are associated with
susceptibility to CD, UC, ankylosing spondylitis (AS,
MIM 106300), and leprosy (MIM 609888)16–20 (Table S8).
Strong association of five SNPs (rs3810936, rs6478108,
rs6478109, rs7848647, and rs7869487) in the TNFSF15
region with CD was first reported for a Japanese popula-
tion,16 and the finding was replicated in an indepen-
dent Japanese population and in European-descent and
Korean populations.21–25 Another SNP within TNFSF15
(rs4263839) is also associated with susceptibility to CD in
populations of European descent.17,20,26 In addition, the
risk alleles of the SNPs were significantly associated with
TNFSF15mRNA expression in peripheral blood.27,28 Given
that there exists strong LD among SNPs in TNFSF15,
including those in the promoter region (rs6478109 andan Journal of Human Genetics 91, 721–728, October 5, 2012 725
rs7848647) and introns (rs4263839 and rs4979462), it is
very probable that the PBC susceptibility haplotype con-
taining rs4979462 also influences TNFSF15 mRNA expres-
sion. Additionally, TNFSF15 signaling via DR3 synergizes
with interleukin-12 (IL-12) and IL-18 to promote IFN-g
production.15 The IL-12 signaling pathway includes
IL12A and IL12RB (MIM 601604), variants of which have
been identified as PBC susceptibility loci in previous
GWASs of peoples of European ancestry, and has been
implicated as a key player in the pathogenesis of PBC.4–7
STAT4 is essential for IL-12 signal transduction via the
IL-12 receptor (IL12R) for IFN-g production and Th1 polar-
ization.29 Thus, the evidence that TNFSF15 and STAT4
were identified and confirmed as PBC susceptibility loci
in the present studymight indicate that the IL-12 signaling
pathway via IL12R is also operative in PBC pathogenesis in
Japanese populations, as it is in populations of European
descent.
POU2AF1 is a B cell-specific transcriptional factor that co-
activates octamer-binding transcriptional factors POU2F1
(MIM164175) and POU2F2 (MIM164176) onB cell-specific
promoters; thus, POU2AF1 is essential for B cell matura-
tion and germinal center formation.30 The E-twenty six
transcription factor Spi-B was recently identified as a direct
target of the coactivator POU2AF1.31 Spi-B is an important
mediator of both B cell receptor signaling and early T cell
lineage decisions.32,33 Spi-B also induces IL7R-induced
CD40 (MIM 109535, MIM 300386) expression.34 Given
that Spi-B has been identified as a PBC susceptibility gene
in previous GWASs of peoples of European ancestry,6,7,35
variation of POU2AF1 might function along with Spi-B in
this pathway of B cell signaling and differentiation. The
lack of POU2AF1 reportedly prevents the development of
autoimmunity in Aiolos (also known as IKZF3) mutant
mice, which have a systemic lupus erythematosus (MIM
152700)-like phenotype, and in MRL-lpr mice.36,37 IKZF3
and IL7R were both replicated and confirmed as PBC
susceptibility loci in this study; IKZF3 functions as a
transcription factor that participates in the generation of
high-affinity bone marrow plasma cells responsible for
long-term immunity, and IL7R participates in pre-B cell
expansion.38,39 Collectively, these results strengthen the
notion that the B cell signaling pathway is involved in
the development of PBC.
In conclusion, TNFSF15 and POU2AF1 were identified as
significant susceptibility loci for PBC in a Japanese popula-
tion. Our results provide further evidence for the presence
of (1) ethnic differences in genetic susceptibility loci (i.e.,
TNFSF15, IL12A, and IL12RB2), (2) a new autoimmune
pathway (i.e., TNFSF15 signaling) shared with other auto-
immune diseases (CD, UC, and AS), and (3) common
pathogenic pathways such as B cell differentiation (i.e.,
POU2AF1, IKZF3, and SPIB), IL-12 signaling (i.e., IL12A,
IL12RB2, and STAT4), and T cell activation (i.e., CD80)
for the development of PBC in individuals of European
descent and Japanese individuals (Table S8). Functional
analysis of these genetic loci, as well as the identification726 The American Journal of Human Genetics 91, 721–728, Octoberof additional susceptibility loci associated with PBC in
eastern Asian populations, should facilitate the analysis
of the pathogenesis of PBC worldwide and aid the develop-
ment of rationale for therapies in the future.Supplemental Data
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